BST Position Update – November 6, 2015

| November 6, 2015

BST Position Update

. . . . Threshold Pharmaceuticals (NASD: $THLD) – Buy 

Threshold Pharmaceuticals announced last month that they have received two U.S. patents for Tarloxotinib Bromide, a promising treatment for non-small cell lung cancer and patients with squamous cell cancers of the head and neck or skin. The drug is currently in a Phase 2 clinical trial and a second trial for the drug will be initiated later this year to test its response on advanced head and neck cancer.

I first recommended this stock when it began its trial on Evofosfamide in 2014, which is now in pivotal Phase 3 clinical trials. Threshold now has the most advanced hypoxia-activated products in clinical development with Tarloxotinib Bromide and Evofosfamide.

The stock is currently trading at $4.35 and my buy up to price is $4.80. I think we will see continued gains from this promising pharma company. Get in now while you still can…


. . . . Dyax Corp. (NASDAQ: $DYAX) – Sell 

I pointed out earlier this year that Dyax was a takeover candidate after the approval of the drug called DX-2930.  Well, the buyout offer from Shire $SHPG for $5.9 billion came this week.  Shareholders will also receive a non-tradable contingent value right worth $4.00 in cash representing and additional amount of $646 million.

Since the announcement, the stock has been on fire! The stock is currently trading at $34.77 and the original purchase price was $15.44. That’s up over 125%!

Let’s sell this stock and cash in on these profits.

Sell DYAX now.

. . . . Progenics Pharmaceuticals (NASDAQ: $PGNX) – Hold

Last month results from Progenics’ 1404 imaging agent Phase 2 clinical trial were presented at the Annual European Association of Nuclear Medicine (EANM). 1404 is a prostate specific membrane antigen (PSMA) targeted small molecule labeled with technetium-99m designed to “visualize” prostate cancer. The trial has shown success for 1404 to better assess the stage and extent of a patient’s prostate cancer versus biopsy.

The company has also announced plans to acquire EXINI Diagnostics AB $PUBL, a leader in the developmental software solutions for medical diagnostic imaging. This will allow Progenics with in-house developmental capabilities to manufacture medical imaging software using its own prostate imaging agent 1404.

Let’s hold onto PGNX and see what develops with 1404 and their new medical diagnostic imaging capabilities.

Hold PGNX.

Action To Take

  • Buy THLD
  • Sell DYAX
  • Hold PGNX

Category: BST Update

About the Author ()

Comments are closed.